Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mimedx (MDXG) Research & Development (2016 - 2026)

Mimedx's Research & Development history spans 16 years, with the latest figure at $4.1 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 24.4% to $4.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.9 million, a 23.99% increase, with the full-year FY2025 number at $15.1 million, up 22.33% from a year prior.
  • Research & Development hit $4.1 million in Q1 2026 for Mimedx, down from $4.8 million in the prior quarter.
  • Over the last five years, Research & Development for MDXG hit a ceiling of $6.0 million in Q1 2022 and a floor of -$4.7 million in Q4 2022.
  • Historically, Research & Development has averaged $3.3 million across 5 years, with a median of $3.5 million in 2023.
  • Biggest five-year swings in Research & Development: tumbled 66.6% in 2022 and later soared 151.46% in 2023.
  • Tracing MDXG's Research & Development over 5 years: stood at -$4.7 million in 2022, then soared by 151.46% to $2.4 million in 2023, then skyrocketed by 46.77% to $3.6 million in 2024, then soared by 33.32% to $4.8 million in 2025, then fell by 13.04% to $4.1 million in 2026.
  • Business Quant data shows Research & Development for MDXG at $4.1 million in Q1 2026, $4.8 million in Q4 2025, and $3.7 million in Q3 2025.